drug

ethyl-eicosapentaenoic acid

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Yale University
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Investigational (via trials)
Schizophrenia Prodrome

Trials

1
Ethyl-EPA Treatment of Prodromal Patients
NCT00634361Phase 2, Phase 3Completed

KOLs & investigators

1
Scott W. Woods, MDKOL score 8

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Yale University
company
trial
Ethyl-EPA Treatment of Prodromal Patients
PHASE2, PHASE3
trial
indication
Schizophrenia Prodrome
indication
KOL
Scott W. Woods, MD
KOL score 8
person